Jiawei Zhong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiawei Zhong has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aohan Zu
Zhejiang Univ, Affiliated Hosp 1, Dept Cardiol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
1 shared publication - Biqi Zhang
Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310003 Hangzhou, Zhejiang, China
1 shared publication Chenyu Zuo
Shanghai Centennial Sci Co Ltd, Shanghai 200032, Peoples R China
1 shared publicationDongchen Zhou
Zhejiang Univ, Affiliated Hosp 1, Dept Cardiol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
1 shared publication- Jiajia Jiang
Zhejiang Univ, Affiliated Hosp 1, Dept Cardiol, Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
1 shared publication Jianwei Xuan
Sun Yat Sen Univ, Guangzhou 510275, Guangdong, Peoples R China
1 shared publication
Latest Publications
- Open Access
- 1 February 2024
- Vol. 13 (2) , e230035
Radiofrequency ablation using the ThermoCool SmartTouch Catheter guided by ablation index versus antiarrhythmic drugs in atrial fibrillation treatment in China: a cost-consequence analysis
Aim: To evaluate the costs and consequences of two front-line atrial fibrillation (AF) treatments from Chinese healthcare system perspective: radiofrequency catheter ablation (RFCA) using ThermoCool SmartTouch Catheter guided by Ablation Index (STAI), in comparison to antiarrhythmic drugs (AADs). Patients & methods: We simulated clinical and economic consequences for AF patients initially receiving STAI or AADs using a short-term decision tree model leading to a 10-year long-term Markov model. The model projected both clinical consequences and costs associated with, among others, AF, heart failure (HF), strokes, and deaths due to AF or AF related complications. Data informing the models included combination of a local real-world study and published clinical studies. Results: STAI was advantageous versus AADs on all 4 main clinical outcomes evaluated; AF: 25.83% lower (12.84% vs 38.67%), HF: 2.22% lower (1.33% vs 3.55%), stroke or post stroke: 1.82% lower (10.00% vs 11.82%) and deaths due to AF or AF related complications: 0.64% lower (4.11% vs 4.75%). The average total cost per patient in STAI group was yen 16,682 lower ( yen 123,124 vs yen 139,806). The one-way sensitivity analysis indicated that the difference in total cost was most sensitive to annual AF recurrence probability in AADs-treated patients. Probabilistic sensitivity analysis indicated a 98.5% probability that RFCA treatment would result in cost savings by the end of the 10th year. Conclusion: Radiofrequency catheter ablation using SmartTouch catheter guided by Ablation Index was superior to AADs as the first-line AF treatment in Chinese setting with better clinical outcomes and at lower costs over a 10-year time horizon.
- 1 February 2024
- Vol. 13 (2) , e230035
Open AccessRadiofrequency ablation using the ThermoCool SmartTouch Catheter guided by ablation index versus antiarrhythmic drugs in atrial fibrillation treatment in China: a cost-consequence analysis
Aim: To evaluate the costs and consequences of two front-line atrial fibrillation (AF) treatments from Chinese healthcare system perspective: radiofrequency catheter ablation (RFCA) using ThermoCool SmartTouch Catheter guided by Ablation Index (STAI), in comparison to antiarrhythmic drugs (AADs). Patients & methods: We simulated clinical and economic consequences for AF patients initially receiving STAI or AADs using a short-term decision tree model leading to a 10-year long-term Markov model. The model projected both clinical consequences and costs associated with, among others, AF, heart failure (HF), strokes, and deaths due to AF or AF related complications. Data informing the models included combination of a local real-world study and published clinical studies. Results: STAI was advantageous versus AADs on all 4 main clinical outcomes evaluated; AF: 25.83% lower (12.84% vs 38.67%), HF: 2.22% lower (1.33% vs 3.55%), stroke or post stroke: 1.82% lower (10.00% vs 11.82%) and deaths due to AF or AF related complications: 0.64% lower (4.11% vs 4.75%). The average total cost per patient in STAI group was yen 16,682 lower ( yen 123,124 vs yen 139,806). The one-way sensitivity analysis indicated that the difference in total cost was most sensitive to annual AF recurrence probability in AADs-treated patients. Probabilistic sensitivity analysis indicated a 98.5% probability that RFCA treatment would result in cost savings by the end of the 10th year. Conclusion: Radiofrequency catheter ablation using SmartTouch catheter guided by Ablation Index was superior to AADs as the first-line AF treatment in Chinese setting with better clinical outcomes and at lower costs over a 10-year time horizon.